Kintara Therapeutics to Participate in Benzinga Biotech Small Cap Conference

Rhea-AI Summary

Kintara Therapeutics (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will speak at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 9:45 am ET. Investors can access a corporate presentation after registering for the event. Kintara focuses on developing innovative cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. Both drugs are entering late-stage clinical trials, showcasing strong clinical efficacy and safety profiles.

SAN DIEGO, March 17, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that its Chief Executive Officer Saiid Zarrabian will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021.  Mr. Zarrabian will present on March 24, 2021 at 9:45 am ET.

Investors can view Mr. Zarrabian's general corporate presentation once they register for the conference here and can also request a 1x1 meeting with Mr. Zarrabian.

About Kintara
Located in San Diego, California, Kintara (Nasdaq: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.

REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and Linkedin.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study.  Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.  The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.  These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2020, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACTS
Investors
CORE IR
516-222-2560
ir@coreir.com

Media
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/kintara-therapeutics-to-participate-in-benzinga-biotech-small-cap-conference-301249153.html

SOURCE Kintara Therapeutics

FAQ

When will Kintara Therapeutics CEO present at the Benzinga Biotech Small Cap Conference?

Saiid Zarrabian will present on March 24, 2021, at 9:45 am ET.

What is Kintara Therapeutics focusing on in its clinical trials?

Kintara is focused on developing VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer.

How can investors access the Kintara presentation at the Benzinga conference?

Investors can view the presentation after registering for the conference.

What are the clinical results for Kintara's REM-001 therapy?

REM-001 has shown an 80% complete response rate in evaluated lesions for cutaneous metastatic breast cancer.

What mechanism of action does VAL-083 utilize?

VAL-083 is a first-in-class small-molecule chemotherapeutic with a novel mechanism effective against various cancers.